Sara Escalera

Mrs. Sara Escalera

University of Valladolid
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Alessandra GirottiAlessandra Girotti
Alessandra Girotti
Sara EscaleraSara Escalera
Sara Escalera
IAIrene Alonso-Sampedro
Irene Alonso-Sampedro
Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
Juan Gonzalez-Valdivieso
FAF. Javier Arias
F. Javier Arias
Biomaterials science is one of the most rapidly evolving fields in biomedicine. However, although novel biomaterials have achieved well-defined goals, such as the production of devices with improved biocompatibility and mechanical properties, their development could be more ambitious. Indeed, the integration of active targeting strategies has been shown to allow spatiotemporal control of cell–material interactions, thus leading to more specific and better-performing devices. This manuscript reviews recent advances that have led to enhanced biomaterials resulting from the use of natural structural macromolecules. In this regard, several structural macromolecules have been adapted or modified using biohybrid approaches for use in both regenerative medicine and therapeutic delivery. The integration of structural and functional features and aptamer targeting, although still incipient, has already shown its ability and wide-reaching potential. In this review, we discuss aptamer-functionalized hybrid protein-based or polymeric biomaterials derived from structural macromolecules, with a focus on bioresponsive/bioactive systems.

3 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PGPau González
Pau González
CGCarlos González-Fernández
Carlos González-Fernández
AFAlfredo Maqueda Fernández
Alfredo Maqueda Fernández
VPVirginia Pérez
Virginia Pérez
Sara EscaleraSara Escalera
Sara Escalera
FRFrancisco Javier Rodríguez
Francisco Javier Rodríguez
Despite the promising potential of hydrogel-based therapeutic approaches for spinal cord injury (SCI), the need for new biomaterials to design effective strategies for SCI treatment and the outstanding properties of silk-elastin-like polymers (SELP), the potential use of SELPs in SCI is currently unknown. In this context, we assessed the effects elicited by the in vivo acute intraparenchymal injection of an SELP named (EIS)2-RGD6 in a clinically relevant model of SCI. After optimization of the injection system, the distribution, structure, biodegradability, and cell infiltration capacity of (EIS)2-RGD6 were assessed. Finally, the effects exerted by the (EIS)2-RGD6 injection—in terms of motor function, myelin preservation, astroglial and microglia/macrophage reactivity, and fibrosis—were evaluated. We found that (EIS)2-RGD6 can be acutely injected in the lesioned spinal cord without inducing further damage, showing a widespread distribution covering all lesioned areas with a single injection and facilitating the formation of a slow-degrading porous scaffold at the lesion site that allows for the infiltration and/or proliferation of endogenous cells with no signs of collapse and without inducing further microglial and astroglial reactivity, as well as even reducing SCI-associated fibrosis. Altogether, these observations suggest that (EIS)2-RGD6—and, by extension, SELPs—could be promising polymers for the design of therapeutic strategies for SCI treatment.


7 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
Juan Gonzalez-Valdivieso
JGJavier Gutiérrez
Javier Gutiérrez
Jonathan Alexander Vasquez CaleroJonathan Alexander Vasquez Calero
Jonathan Alexander Vasquez Calero
Sara EscaleraSara Escalera
Sara Escalera
RMRaquel Muñoz-Martínez
Raquel Muñoz-Martínez
Alessandra GirottiAlessandra Girotti
Alessandra Girotti
Over the past decade, the use of nanomaterials and nanomedical devices has been increasingly explored for cancer treatment. Although the outcomes of conventional therapies have improved patient survival, these approaches still present important limitations for some types of cancer and metastasis. Challenges such as poor drug accumulation in solid tumors and lack of specificity and selectivity can be addressed through alternative nanomedicine-based treatments. Among the wide range of nanoplatforms whose composition and shape have been designed for cancer treatment, this review focuses specifically on those based on natural proteins, including advanced carriers and engineered proteins bearing active targeting and/or therapeutic agents. The objective of this review is to provide a comparative and translational analysis of protein-based nanomaterials for cancer therapy, highlighting their unique characteristics, such as biocompatibility, biodegradability, and the ability to integrate bioactive peptides that can trigger or respond to tumor-specific or altered physiological stimuli. Several protein-based nanomedical devices have been developed for theranostic applications, demonstrating enhanced performance in tumor imaging and cancer treatment. This review introduces a structured analytical framework that classifies protein-based nanomaterials according to their biological origin, functional design, and clinical readiness, enabling systematic evaluation across platforms. Rather than providing a descriptive overview, this work offers a structured comparative analysis of protein-based nanomaterials, highlighting design trade-offs, translational challenges, and factors influencing clinical applicability.

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
PGPau González
Pau González
CGCarlos González-Fernández
Carlos González-Fernández
AFAlfredo Maqueda Fernández
Alfredo Maqueda Fernández
VPVirginia Pérez
Virginia Pérez
Sara EscaleraSara Escalera
Sara Escalera
FRFrancisco Javier Rodríguez
Francisco Javier Rodríguez